Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
Want to see APGE full AI Analyst Report?
APGE Stock Chart & Stats
$92.20
-$0.82(-1.65%)
At close: 4:00 PM EST
$92.20
-$0.82(-1.65%)
Day’s Range― - ―
52-Week Range$34.34 - $95.32
Previous CloseN/A
Volume109.80K
Average Volume (3M)1.02M
Market Cap
$6.81B
Enterprise Value$5.03B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$8.05M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 17, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.33
Shares Outstanding61,902,733
10 Day Avg. Volume1,110,015
30 Day Avg. Volume1,019,661
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-19.69
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.33K
Enterprise Value/Ebitda-18.44
Forecast
1Y Price Target
$128.10Price Target Upside38.93% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-4.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Acquisition By AbbVieA definitive all-cash acquisition by AbbVie is a structural outcome that materially de-risks Apogee's standalone execution: it validates the science, grants access to AbbVie's commercialization scale and resources, and converts pipeline value into a concrete strategic exit, reshaping long-term capital needs.
Differentiated Clinical Profile For Lead AssetDurable one-year maintenance results and multi-month dosing for zumilokibart represent a lasting competitive advantage: less‑frequent dosing can drive adherence, payer preference, and market share versus current biologics, supporting stronger commercial sustainability across indications.
Material Non-dilutive Financing And Cash ResourcesAccess to up to $1.3B of non-dilutive capital plus ~ $1.3B cash materially improves funding for Phase 3 and commercialization. This structural capital flexibility reduces equity dilution risk, strengthens late‑stage development resilience, and supports sustained R&D investment through key regulatory milestones.
Bears Say
No Product RevenueLack of product revenue is a persistent structural limitation: without commercial sales, the company remains dependent on partnerships, financing, or an acquirer to realize value. That lack of recurring revenue leaves long‑term profitability and cash self‑sufficiency contingent on future approvals or transactions.
Growing Cash Burn And Negative Operating Cash FlowEscalating negative OCF and FCF indicate structural cash outflows driven by accelerating R&D and operations. Even with recent financings, sustained large burn increases the company's sensitivity to timeline slips or failed trials, requiring ongoing funding or strategic transactions to sustain development.
Transaction And Regulatory ContingenciesThe AbbVie acquisition and any strategic upside depend on shareholder votes, antitrust and regulatory approvals. These contingencies create lasting binary risk: failure or delay would materially change funding, governance and commercialization pathways, leaving the standalone cash burn and execution risks intact.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $34.34 and its highest was $95.31 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Apogee Therapeutics, Inc.’s market cap is $6.81B.
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 50 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$1.06 earnings per share for the quarter, beating the consensus estimate of -$1.066 by $0.006.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -1.07.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 61,902,733 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$1.06 in its last earnings report, beating expectations of -$1.066. Following the earnings report the stock price went up 1.891%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$128.10 (38.93% Upside)
$128.10 (38.93% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
202.55%
12-Months-Change
Fundamentals
Return on Equity
-32.64%
Trailing 12-Months
Asset Growth
81.14%
Trailing 12-Months
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$128.10
▲(38.93% Upside)
Technical Analysis
Ownership Overview
5.96% Insiders
30.33% Mutual Funds
6.75% Other Institutional Investors
44.78% Public Companies and
Individual Investors